Literature DB >> 23415573

Mohs resection and postoperative radiotherapy for head and neck cancers with incidental perineural invasion.

Lauren Kropp1, Christopher J Balamucki, Christopher G Morris, Jessica Kirwan, Armand B Cognetta, Charles B Stoer, William M Mendenhall.   

Abstract

PURPOSE: To update our experience treating cutaneous squamous cell carcinoma (SCC) and basal cell carcinomas (BCC) of the head and neck with incidental perineural invasion (PNI) using Mohs resection followed by radiotherapy (RT). We compare outcomes between head and neck patients with incidental PNI who received Mohs surgery and those who did not.
MATERIALS AND METHODS: From 1987 to 2009, 36 patients were treated with Mohs resection followed by postoperative RT; 82 patients were treated with resection other than Mohs followed by postoperative RT.
RESULTS: The 5-year overall survival and cause-specific survival rates for patients who received Mohs resection plus RT and those who received a non-Mohs resection plus RT were 53% versus 56% (p=0.809) and 84% versus 68% (p=0.0329), respectively. The 5-year local control rates for Mohs and non-Mohs patients were 86% versus 76% (p=0.0606), respectively. The 5-year local-regional control and freedom from distant metastases rates for the Mohs group were 77% and 92%, respectively. The 5-year overall neck control, neck control with elective neck RT, and neck control without elective RT treatment rates for the Mohs group were 91%, 100%, and 82% (p=0.0763), respectively. The rate of grade 3 or higher complication in the Mohs group was 22%, which included bone exposure (N=3), cataract (N=2), chronic non-healing wound (N=2), wound infection (N=1), fistula (N=1), and/or radiation retinopathy (N=1).
CONCLUSIONS: Mohs surgery appears to result in improved local control and cause-specific survival in patients with incidental PNI who receive postoperative RT. Elective nodal RT improves regional control in patients with SCC.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23415573     DOI: 10.1016/j.amjoto.2012.12.017

Source DB:  PubMed          Journal:  Am J Otolaryngol        ISSN: 0196-0709            Impact factor:   1.808


  7 in total

Review 1.  Surgical Management of Periocular Cancers: High- and Low-Risk Features Drive Treatment.

Authors:  Richard C Allen
Journal:  Curr Oncol Rep       Date:  2017-09       Impact factor: 5.075

2.  Role of perineural invasion as a prognostic factor in laryngeal cancer.

Authors:  Massimo Mesolella; Brigida Iorio; Gabriella Misso; Amalia Luce; Mariano Cimmino; Maurizio Iengo; Mario Landi; Pasquale Sperlongano; Michele Caraglia; Filippo Ricciardiello
Journal:  Oncol Lett       Date:  2016-02-24       Impact factor: 2.967

3.  Definitive Radiotherapy for Skin and Adenoid Cystic Carcinoma with Perineural Invasion.

Authors:  William M Mendenhall; Roi Dagan; Curtis M Bryant; Robert J Amdur
Journal:  J Neurol Surg B Skull Base       Date:  2016-03-18

Review 4.  Clinical and Incidental Perineural Invasion of Cutaneous Squamous Cell Carcinoma: A Systematic Review and Pooled Analysis of Outcomes Data.

Authors:  Pritesh S Karia; Frederick C Morgan; Emily Stamell Ruiz; Chrysalyne D Schmults
Journal:  JAMA Dermatol       Date:  2017-08-01       Impact factor: 10.282

5.  Computed tomography-based flap brachytherapy for non-melanoma skin cancers of the face.

Authors:  Emile Gogineni; Haocheng Cai; Dawn Carillo; Zaker Rana; Beatrice Bloom; Louis Potters; Hani Gaballa; Maged Ghaly
Journal:  J Contemp Brachytherapy       Date:  2021-02-18

6.  Evidence-Based Consensus Recommendations for the Evolving Treatment of Patients with High-Risk and Advanced Cutaneous Squamous Cell Carcinoma.

Authors:  Guilherme Rabinowits; Michael R Migden; Todd E Schlesinger; Robert L Ferris; Morganna Freeman; Valerie Guild; Shlomo Koyfman; Anna C Pavlick; Neil Swanson; Gregory T Wolf; Scott M Dinehart
Journal:  JID Innov       Date:  2021-08-25

Review 7.  Review of Perineural Invasion in Keratinocyte Carcinomas.

Authors:  Albert E Zhou; Karl M Hoegler; Amor Khachemoune
Journal:  Am J Clin Dermatol       Date:  2021-06-08       Impact factor: 7.403

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.